Evaluation of the Efficacy and Tolerability of Alendronate versus Denosumab in Kidney Transplant Patients with Reduced Bone Mineral Density.
Sherihan A SayedLamia Mohamed El WakeelAhmad M ElseasiMay Ahmed ShawkiPublished in: Pharmacotherapy (2023)
Denosumab and alendronate showed comparable efficacy in improving BMD at all measured skeletal sites and were safe and well-tolerated, with no serious adverse effects reported in RTRs with low bone mass.